The International Endocervical Adenocarcinoma Criteria and Classification was developed to separate endocervical adenocarcinomas (ECAs) into 2 main categories on the basis of morphology such as human papilloma virus-associated (HPVA) and non-human papilloma virus-associated adenocarcinomas. We aimed to improve the diagnostic accuracy of International Endocervical Adenocarcinoma Criteria and Classification by performing a comprehensive immunohistochemical evaluation and constructing objective immunohistochemical-based algorithms for the classification of these tumors. Tissue microarrays were constructed from 297 of 409 cases used to develop the original classification. Immunostains included p16, p53, estrogen receptor (ER), progesterone receptor, androgen receptor, Vimentin, CK7, CK20, HER2, HIK1083, MUC6, CA-IX, SATB2, HNF-1beta, napsin A, PAX8, CDX2, GATA3, p63, p40, and TTF-1. High-risk human papilloma virus (HR-HPV) was detected by in situ hybridization (ISH) using probes against E6 and E7 mRNA expressed in 18 different virus types. Vimentin, ER, and progesterone receptor were expressed in a significant minority of ECAs, mostly HPVAs, limiting their use in differential diagnosis of endometrioid carcinoma when unaccompanied by HPV-ISH or p16. HR-HPV ISH had superior sensitivity, specificity, and negative and positive predictive values compared with p16, as published previously. HNF-1beta did not have the anticipated discriminatory power for clear cell carcinoma, nor did MUC6 or CA-IX for gastric-type carcinoma. HNF-1beta and napsin A were variably expressed in clear cell carcinoma, with HNF-1beta demonstrating less specificity, as it was ubiquitously expressed in gastric-type carcinoma and in the majority of HPVassociated mucinous (predominantly intestinal-type and invasive ECA resembling stratified mucin-producing intraepithelial lesion [iSMILE]) and usual-type carcinomas. HIK1083 was expressed in nearly half of gastric-type carcinomas, but not in the vast majority of other subtypes. GATA3 was positive in 10% of usual-type adenocarcinomas and in single examples of other subtypes. Rare gastric-type and HPVA mucinous carcinomas displayed HER2 overexpression. Androgen receptor was positive in 6% of usual-type adenocarcinomas. Aberrant p53 expression was found in only 3.6% of usual-type HPVA carcinomas, but it was more prevalent in mucinous (intestinal type and iSMILE) HPVAs and non-human papilloma virus-associates (particularly in gastric-type carcinoma, > 50% of cases). The following diagnostic classification algorithms were developed with the above data. Carcinomas without overt cytoplasmic mucin (endometrioid, usual-type endocervical, clear cell, and mesonephric carcinomas) can be subclassified using HR-HPV ISH, ER, and GATA3, whereas carcinomas with easily appreciated cytoplasmic mucin (endometrioid carcinoma with mucinous features, HPVA mucinous, and gastric-type carcinomas) can be subclassified with HR-HPV ISH and ER.
I
nvasive endocervical adenocarcinomas (ECAs) are currently classified on the basis of subjective descriptive morphologic characteristics, particularly cytoplasmic features, 1 assessed on hematoxylin and eosin (H&E)-stained slides. This has led to heterogenous categories of ECAs that, with only occasional exceptions, are not useful in clinical management. 2 A panel of pathologists from 7 different international institutions proposed a new classification scheme that separates ECAs into 2 main categories, using H&E slides: human papilloma virus-associated adenocarcinoma (HPVA), and non-human papilloma virus-associated adenocarcinoma (NHPVA). 3 Data from studies of vulvar squamous carcinoma and carcinoma in nongynecologic sites, such as head and neck, suggest that a classification based on pathogenesis is clinically informative and reproducible. [4] [5] [6] [7] The validity of this new classification (International Endocervical Adenocarcinoma Criteria and Classification [IECC] ) is supported by clinical data and HPV status. 3 Compared with HPVAs, NHPVAs present at a more advanced stage and are associated with more aggressive clinical behavior, with higher recurrence rates and worse overall survival. 8 According to the IECC, the most frequent subtype in the HPVA category is usual-type ECA, 95% being HPV-positive, ascertained using an RNA-based in situ hybridization (ISH) assay that recognizes 18 different types of high-risk human papilloma virus (HR-HPV). In a recently published report, gastric-type, clear cell, endometrioid, serous, and mesonephric carcinomas were HPV negative. 3 Similar results have been reported by other investigators. 1, [9] [10] [11] [12] HPVA carcinomas include those lacking obvious intracytoplasmic mucin (ie, usual type) and those containing intracytoplasmic mucin, such as mucinous not otherwise specified (NOS), intestinal mucinous, signet-ring cell, and invasive ECA resembling stratified mucin-producing intraepithelial lesion (iSMILE). As both gastric-type carcinomas (NHPVAs) and HPVA-associated mucinous carcinomas contain intracytoplasmic mucin, recognition of the morphologic features associated with HPV infection (such as conspicuous floating mitoses and apoptosis), HPV ISH and immunohistochemistry (IHC) can be used to refine the diagnosis.
Commonly encountered problems in differential diagnoses include distinguishing between the following: endometrioid and usual-type endocervical carcinoma; mucinous carcinomas of HPVA type and gastric-type carcinoma; clear cell and mesonephric carcinoma; clear cell and gastric-type carcinoma; primary endocervical and metastatic mucinous carcinoma; and endocervical and endometrial primary carcinoma. A recent abstract examining interobserver diagnostic concordance using the IECC system reported only fair interobserver agreement (K = 0.33) among 7 experienced gynecologic pathologists (although majority agreement was achieved in 74% of 87 cases, with the highest levels of agreement reported for gastric-type and clear cell carcinomas). 13 Cases with majority agreement had excellent correlations with predicted HPV status, but the lowest levels of agreement were found with subtyping variants of HPVA tumors. These figures invoke the need for more precise biomarkers or combinations thereof for a meaningful and reproducible classification of invasive ECAs.
In an attempt to improve objective diagnostic accuracy, we performed a comprehensive IHC evaluation of a wide range of ECA types, as classified by the IECC.
MATERIALS AND METHODS
Institutional approval for this study was obtained from each of the participating centers.
Patient Selection
Slides from 409 invasive ECAs with at least a 5-year follow-up were collected. In situ carcinomas, squamous carcinomas, adenosquamous carcinomas, tumors with a neuroendocrine component, carcinosarcomas, and any tumor demonstrating clinical, macroscopic, or microscopic features, suggesting a lower uterine segment, uterine corpus, or adnexal primary were excluded. Tumors treated with neoadjuvant chemotherapy and/or radiotherapy were also excluded. Types of specimens included were conizations/trachelectomies/ hysterectomies and exenterations with lymph node dissection; however, biopsy and LEEP specimens were excluded.
Morphologic Assessment
All subtypes of ECA were included in this study. Assessment of morphology required examination of all H&E slides with tumor present (an average of 12 slides per case). A consensus diagnosis was reached in every case, with at least 2 and as many as 4 study pathologists reviewing slides at a multihead microscope. Tumors were classified according to the new classification proposal (IECC) 8 ( Fig. 1 ; IECC criteria in Table 1 ).
Tissue Microarray Construction and IHC Study
Tissue microarrays (TMAs) were constructed using previously described methods. 15, 16 These included 297 cases from New York, Boston, Mexico, Japan, and Romania. The following stains were performed: p16, p53, progesterone receptor (PR), androgen receptor (AR), Vimentin, HER2, HIK1083, MUC6, CA-IX, SATB2, HNF-1beta, PAX8, CK7, CK20, CDX2, GATA3, p63, and p40 ( Table 2) . Each of the tumors from the centers in New York, Mexico, and Romania was represented by three 0.6 mm cores, whereas cases from Japan were represented by single 3 mm cores. Except for estrogen receptor (ER), CK20, napsin A, and GATA3, which were scored by 1 pathologist (R.A.S. or T.K.), stains were scored by 2 study pathologists (R.A.S. and S.S.) reaching a consensus. Disagreements were extremely rare (∼2% to 3%) and were adjudicated by re-reviewing stated criteria for positivity, as described below. In some cases, only 1 or 2 cores remained on the stained slide and were still considered eligible for scoring. p16 was interpreted as positive if diffuse and block-like staining was found in all cores; no staining or patchy staining was interpreted as negative. p53 was scored as positive if ≥ 75% of tumor cell nuclei were strongly positive or if no staining was present in the background of an intact internal control. ER, PR, AR, HPVA mucinous carcinomas include mucinous ECA, not otherwise specified, mucinous ECA of intestinal type, mucinous ECA of signet-ring cell type, and "iSMILE". 14 *Endometrioid carcinoma is very rarely encountered as an endocervical primary tumor. Little is known about its derivation, clinical correlates, and biological properties. 3 PAX8, CK7, CK20, HNF-1beta, and napsin A were interpreted as positive if > 25% (score 3 or 4) of tumor cell nuclei or cytoplasm (CK7, CK20, and napsin A) were stained as follows: score 0: <5%; score 1+: 5% to 10%; score 2+: 11% to 25%; score 3+: 26% to 75%; score 4+: > 75%. Vimentin was scored as positive if ≥ 50% of tumor cells showed membranous/cytoplasmic staining. HER2 was scored using the CAP guidelines for gastric carcinoma: 3+ membranous positive. 17 HIK 1083, MUC6 and CA-IX, SATB2, GATA3, p63, p40, and CDX2 were considered positive if any nuclear staining was noted in > 5% of tumor cells. HIK 1083 is currently not available in the United States.
HPV Detection
HPV detection for HR-HPV subtypes was performed on all ECAs in the TMA that had sufficient tissue to score and had not been improperly fixed or stored (n = 168). HPV-ISH with a chromogen was performed using the Advanced Cell Diagnostics (ACD) (Hayward, CA) RNAscope system (catalogue no. 312598). The RNAscope Probe "HPV HR18" contains probes targeting E6 and E7 mRNA for the following high-risk subtypes: HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 , and 82. The methodology and interpretation were discussed in detail in a previous paper. 18 
Statistical Analysis
Standard statistical methods were used, including analysis of variance, utilizing the statistical package program STATA 13 (StataCorp). 
RESULTS

P16 and HPV-ISH
These data were recently reported. 3 Ninety-five percent of usual-type adenocarcinomas were HPVpositive, whereas 90% were p16-positive (Fig. 2) . All IECC HPV-associated mucinous carcinomas (mucinous NOS, mucinous intestinal, and invasive mucinous carcinomas with a resemblance to iSMILE) were HPVpositive, whereas only 69% were p16-positive. No gastric, endometrioid, serous, or clear cell carcinomas were HPVpositive, although 33% of gastric-type and 17% of clear cell carcinomas were p16-positive. The ACD RNAscope HPV HR18 probe set had superior sensitivity, specificity, and positive and negative predictive values (0.955, 0.968, 0.992, and 0.833, respectively), compared with p16 (0.872, 0.632, 0.907, and 0.545, respectively), in identifying HPVA usual and mucinous adenocarcinomas.
Markers Associated With Differentiation
Results are summarized in Table 3 and in Figures 3-5 . Expression of these markers is not related to HPV. Nearly all adenocarcinomas were CK7-positive, whereas CK20 expression was negative in all cases. At least 75% of all tumor types that were well represented in the TMA were PAX8-positive, with the notable exception of iSMILEs, which only displayed 14.3% positivity. Vimentin was positive in 13% of usual-type, 13% of iSMILE, 7.4% of gastric-type, and 14% of clear cell carcinomas. All HPV-associated mucinous carcinomas aside from iSMILEs (mucinous NOS and intestinal type) were Vimentin-negative. PR was expressed in 20% of usual-type carcinoma and in small numbers of other tumor types, whereas ER was expressed in 5% of usual-type carcinomas. Sixty-five percent of ER-positive tumors were PR-positive and 30% of PR-positive tumors were ER-positive. Only 3 ECAs were classified as endometrioid. Of these, ER and PR were expressed in only 1 example each, 2 were PAX8-positive, and all expressed CK7.
A summary of results for markers that have been proposed to be characteristically expressed in specific tumor types (ie, HNF-1beta, napsin A, HIK1083, MUC6, CA-IX, GATA3, and TTF-1), and possibly useful in differential diagnosis, as well as those related to intestinal differentiation (CDX2 and SATB2), can be found in Table 4 . HNF-1beta did not have the anticipated discriminatory power to distinguish clear cell carcinoma from other tumor types, nor did MUC6 or CA-IX for gastric-type carcinoma. In addition and adenocarcinoma NOS. The single mesonephric carcinoma in the study was not adequately represented in the TMA used for GATA3 expression. TTF-1 was negative in all tumor types studied. p63 and p40, markers of squamous differentiation, showed a discrepant rate of positivity, as p63 was positive in only 3 cases (1 usual type, 1 gastric type, and 1 iS-MILE), whereas p40 positivity was encountered in 12% of usual-type adenocarcinomas, 29% of iSMILEs (Fig. 3) , and 43% of adenocarcinomas NOS. p40 was also present as a rim of positive cells at the periphery of the tumor cell nests in iSMILE (Table 5) .
Markers of Possible Therapeutic Importance
HER2 and AR results are presented in Table 6 . HER2 overexpression was found in only 5 adenocarcinomas in the entire cohort. Most tumors were negative for both markers, with only 3.8% of the gastric type (Fig. 5) and 12 .5% of the iSMILE type positive for HER2. AR positivity was demonstrated in 5.9% of usual-type adenocarcinomas and in rare examples of other tumor types. Twenty-two percent of PR-positive tumors were AR-positive.
P53-A Marker of Possible Prognostic Significance
These results are presented in Table 7 . Among HPVAs, aberrant p53 expression was found in only 3.6% of usual-type carcinomas (Fig. 3) , but was more commonly found in both HPVAs of mucinous type (Fig. 4) and in NHPVAs, including 3 of 16 mucinous HPVAs (2 of them iSMILEs) and 52% of gastric-type carcinomas.
DISCUSSION
Recent studies have demonstrated that, unlike cervical squamous cell carcinomas, ∼15% of ECAs are HPVunrelated (NHPVAs). 1, 3, 19 HPVA ECAs, the most frequent variant being usual type, have a better prognosis than NHPVA ECAs, of which the most frequent variant is the gastric type. 3, 8 HPV status provides not only prognostic information, but also evidence with regard to site of origin, as endometrial, ovarian, and colorectal adenocarcinomas are HPV negative. [20] [21] [22] To expand on this notion and assess the immunophenotype of ECA variants, with the goal of increasing diagnostic accuracy, we performed an extensive IHC evaluation of up to 297 ECAs, as classified by IECC and represented in TMAs.
Our results for PAX8, Vimentin, and ER/PR are broadly concurrent with those reported in the literature. 9, [22] [23] [24] [25] [26] [27] The majority of ECAs (all types) are PAX8-positive, although a significant minority, particularly iSMILE adenocarcinomas, are negative. Extensive PAX8 positivity should be useful in assigning a carcinoma of unknown origin to the gynecologic tract, provided that renal and thyroid carcinomas-which are highly unlikely to metastasize to the cervix-are excluded. Although most mucinous carcinomas, irrespective of HPV status, were negative for Vimentin, 12% to 14% of usual-type and clear cell carcinomas were at least focally positive for that marker. Up to 24% and 12% of usual-type adenocarcinomas showed at least focal PR and ER expression, respectively, which could create difficulties in the differential diagnosis of these tumors and endometrial endometrioid carcinomas. Both HPV-ISH and p16 are far more robust discriminators when endometrial endometrioid carcinoma is a diagnostic consideration, although p16 can be overexpressed in up to 25% of endometrial endometrioid carcinomas, mostly International Federation of Gynaecology and Obstetrics grade 3. 28, 29 As only 3 endometrioid carcinomas of endocervix were found in this large cohort, definite conclusions cannot be drawn about their immunophenotype. Our previous study, 3 summarized herein, reported that the ACD RNAscope HPV HR18 probe set had superior sensitivity, specificity, and positive and negative predictive values, compared with p16, in identifying HPVA usual-type and mucinous adenocarcinomas of the cervix.
With the exception of HIK1083, which is specific but not highly sensitive for gastric-type adenocarcinoma in the current study, other markers of potential value in ECA subtyping (HNF-1beta, MUC6, and CA-IX) did not appear to be useful for this purpose. Approximately 60% to 70% of gastric-type adenocarcinomas were positive for either MUC6 or CA-IX, frequencies somewhat lower than that reported in the literature. 9, 30 It was previously reported that MUC6 fails to distinguish gastric-type from other mucinous ECAs. 30 In this study, 40% of gastric-type carcinomas were HIK1083-positive, less than has been previously reported (75% to 100%), 11, 30 although in 1 study gastric-type adenocarcinomas showed frequent focal or multifocal staining. 11 We, therefore, believe that the relatively low rates of positivity found in this study are likely related to the use of TMAs rather than whole sections. Unfortunately, HIK1083 is not commercially available outside of Japan to our knowledge, limiting its use in routine practice. However, given an ECA with obvious intracytoplasmic mucin, HPV-ISH efficiently separates HPVA from gastric-type carcinoma.
Among ovarian carcinomas, hepatocyte factor-1β (HNF-1beta) was initially found to be a sensitive and specific marker for clear cell carcinoma, 31, 32 although subsequent studies reported diminished specificity in the setting of endometrial clear cell carcinomas. 33 Furthermore, HNF-1beta has also been reportedly expressed in > 90% of gastric-type carcinomas, 9 and our study confirmed this finding. In addition to its limited value in distinguishing between gastric-type and clear cell carcinoma, HNF-1beta was expressed in up to 31 reported that 73% of endometrial clear cell carcinomas overall express this marker; however, this percentage falls to 67.7% when 1 to 3+ scores (out of 12) were considered negative, as in the current study, and they fall as low as 47% when tumors with 4 to 7+ staining are counted as negative (a tumor with 6+ staining might show 26% positivity with strong intensity). Napsin A has recently been touted as a marker with superior performance characteristics compared with HNF-1beta, 34 despite its usually patchy, weak, and granular cytoplasmic staining. Napsin A and HNF-1beta both marked 3 of 7 clear cell carcinomas from the current study, while 57% (4/7) would be regarded "napsin positive" had 1+ staining met criteria for a positive result. Compared with HNF-1beta, napsin A exhibited less frequent staining than HNF-1beta in other tumor types. In 1 study, 34 75% of 49 endometrial CCCs showed > 1+ napsin A staining; in another study on the same topic, 35 66.7% of endometrial clear cell carcinomas were positive, but fully 60% of the total were described as showing "focal" or "rare" staining. In one of the only studies of HNF-1beta and napsin A staining in endocervical clear cell carcinomas, 36 6/7 cases were strongly HNF-1beta positive, but only 3 of 7 were strongly napsin A positive. These studies are difficult to compare because of the different antibody clones used and differing methodologies. Nevertheless, a diagnosis of clear cell carcinoma is based on gold standard histologic features, all of which were present in the 7 tumors studied herein. Our HNF-1beta and napsin A results for clear cell carcinomas remain within the same range as the results from some of the previously published studies, and might have appeared better, had more endocervical clear cell carcinomas and whole sections been available for study.
Tp53 mutation (and aberrant p53 immunostaining) is reportedly significantly less frequent in HPVAs than in other carcinomas of the gynecologic tract, 37 most notably serous and serous-like carcinomas (carcinosarcomas and copy number-high endometrioid and clear cell carcinomas) of the endometrium and ovary. The TCGA study of ECAs reported only 2 adenocarcinomas (1 endocervical and 1 endometrioid) with a Tp53 mutation. 38 Previous studies have suggested a link between stage and Tp53 mutation, 39 which makes sense if one assumes that most high-stage tumors were NHPVAs. A recent series reported aberrant p53 staining in 41% of gastric-type carcinomas, 9 whereas in the current study 51% of gastric-type carcinomas showed aberrant p53 staining. One of 7 clear cell carcinomas, another NHPVA, also showed p53 overexpression, which has been previously described. 36 In general, HPVAs were much less frequently p53-aberrant, although rates ranged from 3% in usual-type to 28% in HPVA mucinous carcinomas (rare intestinal-type HPVAs and iSMILEs), respectively. These results are similar to the findings of Park et al 11 that p53 was diffusely positive in almost half of gastric-type cases, whereas usual-type adenocarcinomas showed mostly negative staining, and other variants showed focal staining. Although wild-type (physiological) p53 staining would be typical of usual-type carcinoma, aberrant staining would not distinguish between other types of ECAs.
This study, which has many of the characteristics of a population-based study, included only limited numbers of rare tumor types subjected to IHC. These included HPVA intestinal-type, mucinous NOS, and signet-ring cell carcinomas, NHPVAs of endometrioid, serous, and mesonephric types, and adenocarcinomas NOS. The immunophenotype of the 3 putative endocervical endometrioid carcinomas (all unassociated with endometriosis) was not typical of endometrial endometrioid carcinoma, further undermining the validity of a diagnosis of endocervical endometrioid carcinoma in the absence of endometriosis, while the adenocarcinoma NOS category is heterogenous, including both HPV-positive and negative adenocarcinomas. With respect to HPVA mucinous ECAs of which only as many as 7 mucinous NOS and intestinal-type adenocarcinomas were studied, iSMILE adenocarcinomas displayed some notable differences, such as more prevalent p40 expression and less prevalent PAX8, with possibly more frequent aberrant p53 staining. These data suggest that iSMILEs might diverge from other mucinous HPVAs, and could be categorized separately if clinical outcomes data support that conclusion.
DIAGNOSTIC ALGORITHMS
Published reports with regard to the immunophenotype of HPVA mucinous adenocarcinomas, "endocervical serous carcinomas," mesonephric carcinomas, and endometrial endometrioid carcinomas can nevertheless be used in concert with the data presented here to construct diagnostic algorithms. For tumors with limited cytoplasmic mucin (Fig. 6) , HR-HPV ISH separates HPVA usual-type adenocarcinoma from endometrial endometrioid, clear cell, and mesonephric carcinomas with 95% accuracy. Expression of ER, very rarely seen in mesonephric and clear cell carcinomas, separates endometrial endometrioid carcinomas from NHPVAs. If using [61] [62] [63] In mucinous adenocarcinomas (Fig. 7) , HPV-ISH again separates NHPVAs from mucinous carcinomas of HPVA type. ER can then be used to separate mucinous carcinoma of endometrium from gastric-type adenocarcinoma, with 75% to 90% expression in the former 64, 65 and no expression in the latter. All of these IHC stains are easily interpreted, but distinguishing between an HPV-positive ECA with only rare nuclear or cytoplasmic signals using HR-HPV ISH and an NHPVA can on rare occasions cause difficulties. These were encountered in 3 of 232 cases. In each case, the questionable signal was compared with the negative control and found to be false positive. p16 can also be used to score challenging cases, but, as detailed in this and other manuscripts, rare HPVAs are p16-negative and many NHPVAs are positive.
The algorithms presented here are meant to provide a diagnostic guide for pathologists lacking close familiarity with usual patterns of HPVAs (ie, invasive SMILE or intestinal-type mucinous HPVAs) and NHPVAs (ie, gastric-type carcinoma, particularly), and cytoarchitectural differences between usual-type and mucinous HPVAs on the one hand and undifferentiated endometrioid carcinomas of endometrium on the other. Following the published IECC guidelines, 3 which are based on evaluation of H&E slides only, a pathologist should be able to confidently distinguish between HPVAs and NHPVAs in most cases. Ancillary testing, such as mRNA-based HR-HPV ISH, or the less sensitive and specific p16, would then be used only in diagnostically difficult cases.
We therefore propose diagnostic IHC algorithms that can be used to distinguish histologic subtypes of ECAs classified by the IECC, as well as endometrial endometrioid carcinomas. These algorithms will improve diagnostic concordance and differentiation between sites of origin.
